{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:25:37Z","timestamp":1792016737229,"version":"4.4.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer&apos;s Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2025.e00811","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T20:23:41Z","timestamp":1766607821000},"page":"e00811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The roles of biomarkers in Alzheimer's disease clinical trials"],"prefix":"10.1016","volume":"23","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailja","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"DeAndrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Leisgang","family":"Osse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00811_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/alz.12450","article-title":"The costs of developing treatments for alzheimer's disease: a retrospective exploration","volume":"18","author":"Cummings","year":"2022","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16049","article-title":"Anti-amyloid antibody treatments for Alzheimer's disease","volume":"31","author":"Perneczky","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib3","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-025-01165-w","article-title":"Biomarker-guided decision making in clinical drug development for neurodegenerative disorders","author":"Cummings","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2025.e00811_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jnc.15757","article-title":"Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease","volume":"165","author":"Kurz","year":"2023","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurot.2025.e00811_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the global CEO initiative on Alzheimer's disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.neurot.2025.e00811_bib8","unstructured":"FDA-NIH Biomarker Working Group. BEST (biomarkers, EndpointS, and other tools) resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US), www.ncbi.nlm.nih.gov\/books\/NBK326791\/(2016 and updates.)."},{"key":"10.1016\/j.neurot.2025.e00811_bib9","doi-asserted-by":"crossref","first-page":"1150510","DOI":"10.3389\/fnagi.2023.1150510","article-title":"Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer's disease","volume":"15","author":"Zhang","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2025.e00811_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","article-title":"Assessment of racial disparities in biomarkers for Alzheimer disease","volume":"76","author":"Morris","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","article-title":"Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial","volume":"81","author":"Brum","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/kjm2.12870","article-title":"Advances in blood biomarkers for Alzheimer disease (AD): a review","volume":"40","author":"Assfaw","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.neurot.2025.e00811_bib13","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","article-title":"The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers","volume":"48","author":"Ashton","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.neurot.2025.e00811_bib14","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/nm1438","article-title":"Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo","volume":"12","author":"Bateman","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.21623","article-title":"A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system","volume":"66","author":"Bateman","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13195-015-0121-6","article-title":"Peripheral and central effects of gamma-secretase inhibition by semagacestat in Alzheimer's disease","volume":"7","author":"Doody","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00811_bib18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","article-title":"Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial","volume":"30","author":"Sevigny","year":"2016","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.neurot.2025.e00811_bib21","series-title":"Early Alzheimer's disease: developing drugs for treatment.Guidance for industry. U.S. Department of health and human services; food and drug administration; center for drug evaluation and research (CDER)","year":"2024"},{"key":"10.1016\/j.neurot.2025.e00811_bib22","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib23","article-title":"Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease","volume":"9","author":"Shcherbinin","year":"2023","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib24","doi-asserted-by":"crossref","first-page":"e1491","DOI":"10.1212\/WNL.0000000000011599","article-title":"Amyloid PET imaging in self-identified Non-hispanic black participants of the Anti-Amyloid in Asymptomatic Alzheimer's disease (A4) study","volume":"96","author":"Deters","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00811_bib25","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1002\/alz.13803","article-title":"Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial","volume":"20","author":"Molina-Henry","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.neurot.2025.e00811_bib27","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","article-title":"Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study","volume":"2","author":"Verberk","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.neurot.2025.e00811_bib28","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213676","article-title":"Associations between changes in levels of phosphorylated tau and severity of cognitive impairment in early Alzheimer disease","volume":"104","author":"Gonzalez-Ortiz","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00811_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s43587-025-00835-z","article-title":"Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials","volume":"5","author":"Ossenkoppele","year":"2025","journal-title":"Nat Aging"},{"key":"10.1016\/j.neurot.2025.e00811_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jama.2025.7817","article-title":"Frequency and clinical outcomes associated with tau positron emission tomography positivity","volume":"334","author":"Moscoso","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2025.e00811_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaneurol.2024.1612","article-title":"Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment","volume":"81","author":"Groot","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib32","doi-asserted-by":"crossref","first-page":"fcae445","DOI":"10.1093\/braincomms\/fcae445","article-title":"Deep learning-based patient stratification for prognostic enrichment of clinical dementia trials","volume":"6","author":"Birkenbihl","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurot.2025.e00811_bib33","doi-asserted-by":"crossref","first-page":"828","DOI":"10.14283\/jpad.2023.83","article-title":"Two-year prognostic utility of plasma p217+tau across the Alzheimer's continuum","volume":"10","author":"Feizpour","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","article-title":"Effects of oral ALZ-801\/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer's disease","volume":"84","author":"Hey","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2025.e00811_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002270","article-title":"APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases","volume":"14","author":"Lanoiselee","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14283\/jpad.2022.48","article-title":"The future of AD clinical trials with the advent of anti-amyloid therapies: an CTAD task force report","volume":"9","author":"Delrieu","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.trci.2018.02.002","volume":"4","author":"Tariot","year":"2018","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib38","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.0000000000001451","article-title":"Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00811_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s13311-021-01047-0","article-title":"Ethical considerations in communicating Alzheimer's disease neuroimaging biomarker test results to symptomatic individuals","volume":"18","author":"Wilkenfeld","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00811_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030780","article-title":"Cardiovascular disease and Alzheimer's disease: the heart-brain axis","volume":"12","author":"Saeed","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.neurot.2025.e00811_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib44","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2025.e00811_bib46","article-title":"The common Alzheimer's disease research ontology (CADRO) for biomarker categorization","volume":"11","author":"Leisgang Osse","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib47","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib48","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMc2111960","article-title":"An appropriate use of accelerated approval - aducanumab for Alzheimer's disease","volume":"385","author":"Dunn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib50","year":"2024","journal-title":"Oncology Center of Excellence (OCE)"},{"key":"10.1016\/j.neurot.2025.e00811_bib51","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2025.2974","article-title":"Concurrent changes in plasma phosphorylated tau 217, tau PET, and cognition in preclinical Alzheimer disease","volume":"82","author":"Insel","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib53","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an Anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib57","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00570","article-title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: strategies and research directions","volume":"22","author":"Cummings","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00811_bib59","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-beta pathway in Alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.neurot.2025.e00811_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14414","article-title":"Biomarker treatment effects in two phase 3 trials of gantenerumab","volume":"21","author":"Bittner","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib62","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1039\/D3OB00509G","article-title":"Recent developments in the chemical biology of amyloid-beta oligomer targeting","volume":"21","author":"Wang","year":"2023","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.neurot.2025.e00811_bib63","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202402622R","article-title":"ALZ-801 prevents amyloid beta-protein assembly and reduces cytotoxicity: a preclinical experimental study","volume":"39","author":"Muramatsu","year":"2025","journal-title":"FASEB J"},{"key":"10.1016\/j.neurot.2025.e00811_bib64","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib65","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer's disease: current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2025.e00811_bib66","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-024-03400-0","article-title":"Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease","volume":"31","author":"Islam","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib67","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease","volume":"31","author":"Horie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib68","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib69","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13195-022-01142-0","article-title":"CSF tau368\/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals","volume":"14","author":"Simren","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib70","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1038\/s41467-024-47286-5","article-title":"Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease","volume":"15","author":"Gonzalez-Ortiz","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2025.e00811_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14458","article-title":"Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis","volume":"21","author":"Khalafi","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib72","doi-asserted-by":"crossref","first-page":"116203","DOI":"10.1016\/j.celrep.2025.116203","article-title":"Biomarker-related phospho-tau217 appears in synapses around Abeta plaques prior to tau tangle in cerebral cortex of preclinical Alzheimer's disease","volume":"44","author":"Hirota","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2025.e00811_bib73","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib74","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.22448","article-title":"Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease","volume":"70","author":"Tarawneh","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib75","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib76","doi-asserted-by":"crossref","first-page":"13496","DOI":"10.18632\/aging.203082","article-title":"MRI-based Alzheimer's disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer's disease","volume":"13","author":"Liu","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.neurot.2025.e00811_bib77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-160621","article-title":"Sample size estimation for Alzheimer's disease trials from Japanese ADNI serial magnetic resonance imaging","volume":"56","author":"Fujishima","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib78","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","article-title":"Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease","volume":"22","author":"Schlepckow","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00811_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24031869","article-title":"Molecular mechanisms of neuroinflammation in aging and Alzheimer's disease progression","volume":"24","author":"Andronie-Cioara","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2025.e00811_bib80","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/alz.13450","article-title":"Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression","volume":"20","author":"Pelkmans","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib82","doi-asserted-by":"crossref","first-page":"102642","DOI":"10.1016\/j.arr.2024.102642","article-title":"Biomarkers of synaptic degeneration in Alzheimer's disease","volume":"104","author":"Cheng","year":"2025","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.neurot.2025.e00811_bib83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40035-024-00420-1","article-title":"The relation of synaptic biomarkers with Abeta, tau, glial activation, and neurodegeneration in Alzheimer's disease","volume":"13","author":"Wang","year":"2024","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.neurot.2025.e00811_bib84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","article-title":"The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease","volume":"12","author":"Colom-Cadena","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib85","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13195-023-01336-0","article-title":"Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum","volume":"15","author":"Goossens","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib86","doi-asserted-by":"crossref","DOI":"10.1177\/1177271920950319","article-title":"Fluid biomarkers for synaptic dysfunction and loss","volume":"15","author":"Camporesi","year":"2020","journal-title":"Biomark Insights"},{"key":"10.1016\/j.neurot.2025.e00811_bib87","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-022-01002-x","article-title":"Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"14","author":"Kivisakk","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-022-01014-7","article-title":"Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study","volume":"14","author":"Vrillon","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer's disease modification","author":"Izzo","year":"2021","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib90","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/s41591-024-02977-w","article-title":"p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial","volume":"30","author":"Shanks","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib91","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/alz.12097","article-title":"In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET","volume":"16","author":"Mecca","year":"2020","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib92","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13195-024-01382-2","article-title":"A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease","volume":"16","author":"van Dyck","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.neurot.2025.e00811_bib93","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.neurobiolaging.2011.09.007","article-title":"Alzheimer's Disease biomarkers working group for the alliance for aging R. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments","volume":"32","author":"Reiman","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurot.2025.e00811_bib94","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13195-023-01327-1","article-title":"Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer's disease continuum: considerations for clinical trials","volume":"15","author":"Scheijbeler","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70104","article-title":"Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia","volume":"21","author":"French","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/ADR-230016","article-title":"Progression of blood-brain barrier leakage in patients with Alzheimer's disease as measured with the cerebrospinal fluid\/plasma albumin ratio over time","volume":"7","author":"Musaeus","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.neurot.2025.e00811_bib97","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.14283\/jpad.2024.126","article-title":"A statistical framework for assessing the relationship between biomarkers and clinical endpoints in Alzheimer's disease","volume":"11","author":"Chen","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib98","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","article-title":"Alzheimer's disease: combination therapies and clinical trials for combination therapy development","volume":"38","author":"Cummings","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2025.e00811_bib99","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.tjpad.2024.100001","article-title":"Key considerations for combination therapy in Alzheimer's clinical trials: perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation","volume":"12","author":"Cummings","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib100","doi-asserted-by":"crossref","first-page":"100328","DOI":"10.1016\/j.tjpad.2025.100328","article-title":"Alzheimer combination therapies: overview and scenarios","volume":"12","author":"Cummings","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib101","doi-asserted-by":"crossref","first-page":"306","DOI":"10.14283\/jpad.2021.21","article-title":"Platform trials to expedite drug development in Alzheimer's disease: a report from the EU\/US CTAD task force","volume":"8","author":"Aisen","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib102","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2025.e00811_bib103","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2025.e00811_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149803","article-title":"Biomarker-guided adaptive trial designs in phase II and phase III: a methodological review","volume":"11","author":"Antoniou","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2025.e00811_bib105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib106","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","article-title":"Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles","volume":"4","author":"Tijms","year":"2024","journal-title":"Nat Aging"},{"key":"10.1016\/j.neurot.2025.e00811_bib107","doi-asserted-by":"crossref","first-page":"eadn3504","DOI":"10.1126\/scitranslmed.adn3504","article-title":"Proteomic analysis of Alzheimer's disease cerebrospinal fluid reveals alterations associated with APOE epsilon4 and atomoxetine treatment","volume":"16","author":"Dammer","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib108","doi-asserted-by":"crossref","first-page":"102776","DOI":"10.1016\/j.sbi.2024.102776","article-title":"Artificial intelligence for drug discovery and development in Alzheimer's disease","volume":"85","author":"Qiu","year":"2024","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.neurot.2025.e00811_bib109","doi-asserted-by":"crossref","first-page":"102497","DOI":"10.1016\/j.arr.2024.102497","article-title":"AI-driven innovations in Alzheimer's disease: integrating early diagnosis, personalized treatment, and prognostic modelling","volume":"101","author":"Kale","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.neurot.2025.e00811_bib110","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1002\/alz.14152","article-title":"CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease","volume":"20","author":"Lizama","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib111","doi-asserted-by":"crossref","first-page":"106575","DOI":"10.1016\/j.nbd.2024.106575","article-title":"An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease","volume":"199","author":"Lizama","year":"2024","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.neurot.2025.e00811_bib113","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/alz.12311","article-title":"Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel","volume":"17","author":"Babiloni","year":"2021","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2025.e00811_bib114","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-020-00632-3","article-title":"Reproducibility of EEG functional connectivity in Alzheimer's disease","volume":"12","author":"Briels","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00811_bib115","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1038\/s41598-023-36713-0","article-title":"PET-validated EEG-machine learning algorithm predicts brain amyloid pathology in pre-dementia Alzheimer's disease","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00811_bib116","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.14283\/jpad.2024.154","article-title":"A pilot electroencephalography study of the effect of CT1812 treatment on synaptic activity in patients with mild to moderate Alzheimer's disease","volume":"11","author":"Vijverberg","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00811_bib117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamaophthalmol.2022.4845","article-title":"Ocular biomarkers for Alzheimer disease dementia: an umbrella review of systematic reviews and meta-analyses","volume":"141","author":"Costanzo","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.neurot.2025.e00811_bib118","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41591-024-03475-9","article-title":"Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment","volume":"31","author":"Butler","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib119","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41746-025-01640-z","article-title":"Alzheimer's disease digital biomarkers multidimensional landscape and AI model scoping review","volume":"8","author":"Qi","year":"2025","journal-title":"npj Digit Med"},{"key":"10.1016\/j.neurot.2025.e00811_bib120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:47:38Z","timestamp":1775306858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747925002892"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00811","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The roles of biomarkers in Alzheimer's disease clinical trials","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00811"}}